bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-13-05: Profiling of APOBEC3 dysregulation in breast cancer
Authors: Hamidi Hamid , Khosh Azad , Rahimi Hamzeh , Ebrahimi Diako 
Published: March 2023

Abstract
DNA of many breast tumors is barraged by C-to-T/G mutations within TCW (W:T,A). These mutations are attributed to the aberrant expression and activity of APOBEC3 enzymes. They have been shown to account for many driver mutations in genes such as PIK3CA, ERBB2, and PPP2R1A, however their precise source and also their roles in tumor development, evolution, and patient survival are debated. Currently, quantification of APOBEC3 expression changes in tumor cells is confounded by the ubiquitous expression of these enzymes in immune infiltrating cells. In this study, we used a novel quantitative biology approach to determine the expression profiles of APOBEC3 enzymes in breast tumor and tumor microenvironment cells from &gt;1,000 patients. We combined diverse datasets including tumor/matched normal RNAseqs, tumor somatic mutations, cell line RNAseqs and mutations, estimates of tumor purities and immune cell compositions, and expression of purified cell populations to show that in breast cancer there is only a single APOBEC3 dysregulation process. This process is subtype-independent and is represented by APOBEC3B upregulation and and extreme APOBEC3C downregulation. Compared to all other tumor types, breast tumors are affected the most by this process.
Citation Format: Hamid Hamidi, Azad Khosh, Hamzeh Rahimi, Diako Ebrahimi. Profiling of APOBEC3 dysregulation in breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-13-05.
Abstract P5-14-07: Somatic mutations of ER and HER2 subtypes exhibit divergent evolutionary trajectories determined by selective epistasis revealed in phylogenetic reconstruction and stage-specific analyses
Authors: Dasari Krishna , Fisk J. Nick , Townsend Jeffrey 
Published: March 2023

Abstract
Estrogen-receptor positive (ER+) and human epidermal growth factor receptor positive (HER2+) subtypes of breast cancers feature distinct histopathologies and prognoses. Their molecular profiles inform subtype-specific treatment combinations and possible therapeutic targets. However, the evolutionary trajectory of somatic mutations within each subtype has not been characterized, despite its utility in prioritizing drug development and therapeutic approaches. Quantifying the selective effects of somatic mutations on cancer conveys the likely efficacy of extant targeted therapies between subtypes. Furthermore, knowledge of epistatic interactions involving targetable mutations enables precision therapy at any stage of tumorigenesis. The strength of these interactions differ between receptor subtypes, mediated by differences in the adaptive landscape of each subtype. To investigate differences in subtype etiologies, we quantified selection on single-nucleotide mutations within ER and HER2 receptor subtypes using an aggregated multi-institutional cohort of tumor samples. We observed differential selection acting on mutations: PIK3CA H1047R is a strongly selected variant for which selection varied significantly based on the receptor subtype, experiencing maximal selection in ER+ HER2﹣ breast cancer. On a stage-specific basis, we show that adaptive landscapes change, altering optimal timings for treatment. We then infer epistasis by 1) stage-specific analysis that suggests likely orderings of mutations, 2) calculation of pairwise selective epistasis amongst mutations, which lends mechanistic explanations to these orderings, and 3) phylogenetic reconstruction of the evolution of ten breast cancers, revealing common orderings that further support inferred selective epistatic interactions. Our estimates of differential and stage-specific selection and epistasis between subtypes suggest distinct adaptive landscapes for breast cancer subtypes. These estimates should inform the development of targeted therapeutics and guide treatment schedules based on molecular profiling of the cancer.
Citation Format: Krishna Dasari, J. Nick Fisk, Jeffrey Townsend. Somatic mutations of ER and HER2 subtypes exhibit divergent evolutionary trajectories determined by selective epistasis revealed in phylogenetic reconstruction and stage-specific analyses [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-14-07.
Abstract P6-01-12: Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery
Authors: Zhu Yidan 
Published: March 2023

Abstract
Abstract Background Previous studies of immune-related gene signatures (IGSs) in breast cancer have attempted to predict the response to chemotherapy or prognosis and were performed using different patient cohorts. The purpose of this study was to evaluate the predictive functions of various IGSs using the same patient cohort that included data for response to chemotherapy as well as the prognosis after surgery. Methods We applied five previously described IGS models in a public dataset of 508 breast cancer patients treated with neoadjuvant chemotherapy. The prognostic and predictive values of each model were evaluated, and their correlations were compared. Results We observed a high proportion of expression concordance among the IGS models (r: 0.56-1). Higher gene expression scores of IGSs were detected in aggressive breast cancer subtypes (basal and HER2-enriched) (P &lt; 0.001). Four of the five IGSs could predict chemotherapy responses and two could predict 5-year relapse-free survival in cases with hormone receptor-positive (HR+) tumors. However, the models showed no significant differences in their predictive abilities for hormone receptor-negative (HR-) tumors. Conclusions IGSs are, to some extent, useful for predicting prognosis and chemotherapy response; moreover, they show substantial agreement for specific breast cancer subtypes. However, it is necessary to identify more compelling biomarkers for both prognosis and response to chemotherapy in HR- and HER2+ cases.
Citation Format: Yidan Zhu. Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-01-12.
Abstract P6-03-08: Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer
Authors: Schinköthe Timo , Kates Ronald , Sprecher Benedikt , Meyer Silja , Tonk Christian Horst , Harbeck Nadia , Schmidt Annette 
Published: March 2023

Abstract
Background: In various fields outside of medicine, AI-supported systems have been established that can predict an undesirable event. The purpose of such systems is to detect events earlier and, if necessary, to be able to prevent them. In medicine, it would be particularly interesting to be able to make such predictions based solely on patient observations. Methods: The usage from 323 patients with advanced breast cancer with a total of 78542 documentation days was used. In addition, the premature termination of use was defined as an undesirable event. The data was then processed and annotated. A deep-learning neural network (NN) classifier was trained on this dataset independently on all documented days to predict this target endpoint. The patient classifier score was computed by averaging over daily scores. Overall classifier accuracy and binary cross entropy loss were computed as performance indicators on training and test data sets (2:1 split). Results: After tuning the hyperparameters, the best-performing NN comprised three hidden layers, each with 88 neurons, using ReLU (linear ramp) activation, and an output layer using sigmoid activation. In the test collective, this model achieved a prediction accuracy of 87%. Discussion: The present application shows for the first time that treatment discontinuation can be predicted with a very high degree of accuracy using patient data alone. This opens up new possibilities in the early detection of possible therapy failures and can represent an essential auxiliary tool in medical care in the future.
Citation Format: Timo Schinköthe, Ronald Kates, Benedikt Sprecher, Silja Meyer, Christian Horst Tonk, Nadia Harbeck, Annette Schmidt. Trained Artificial Intelligence (AI) for Predicting Treatment Termination Based on Patient Observations in Advanced Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-03-08.
Abstract P6-05-07: Oncologic outcomes of pregnancy after surgical treatment of breast cancer 35 years old or under
Authors: Kim Ji Hye , Woo Sang Uk , Lee Jae Bok , Kim Woo Young , Chung Jai Hyun , Kim Yong Yeup 
Published: March 2023

Abstract
Purpose: Recent advances in the treatment of breast cancer has led to the improvement of breast cancer patient’s survival. With prolonged survival of these patients, pregnancy became an important issue, especially in those of young cancer patients aged 35 or under. Increased hormone levels during pregnancy, however, raises concerns of elevating the risk of cancer recurrence. The aim of this study was to validate the notion of increased risk associated with pregnancy after breast cancer treatment in young patients. Methods: From January 2009 to December 2020, newly diagnosed breast cancer patients of 35 years old or under who underwent curative surgery in Korea University Guro Hospital were enrolled in this study. Patients were categorized into 3 groups: nulliparous, pregnancy prior to treatment of breast cancer, and patients with pregnancy after breast cancer treatment. Their overall survival and disease-free survival were evaluated. Results: A total of 126 patients was enrolled in this study. Seventeen patients (13.4%) conceived and successfully delivered. The mean age of enrolled patients was 32.0 years old (± 3.1), and the mean follow up period after surgery was 56.8 months (± 34.2). There was no significant difference in overall survival (p=0.490) and disease-free survival (p=0.740) among different groups. Among 22 patients with re-diagnosis of breast cancer, 2 of them (9%) had breast cancer on their contralateral breast. Conclusion: In young patients, pregnancy after treatment for breast cancer did not affect their overall survival or disease-free survival as compared to nullipara or previously delivered groups. Therefore, pregnancy counseling should not be prevented in young breast cancer patients of 35 years old or under.
Citation Format: Ji Hye Kim, Sang Uk Woo, Jae Bok Lee, Woo Young Kim, Jai Hyun Chung, Yong Yeup Kim. Oncologic outcomes of pregnancy after surgical treatment of breast cancer 35 years old or under [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-05-07.
Abstract P6-05-14: The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy
Authors: Zhu Wenjuan , Li Wanling , Yang Hui , Wang Linying , Guo Jun , Gao Jinnan 
Published: March 2023

Abstract
Background:Chemotherapy has side effects on breast cancer patients, and sleep disturbance is one of the common psychological symptoms. Purpose: This study aimed to examine the incidence of sleep disorders and investigate the relationship between anxiety and depression, hope, social support and sleep disorders in breast cancer patients with chemotherapy in China.Results:Total 350 patients were administered questionnaires, and 329 patients completed the questionnaires. The recovery rate was 94%. The majority of participants reported clinically significant sleep disturbance prior to chemotherapy (67.8%), during chemotherapy (71.8%), and after chemotherapy (72.2%). Pearson correlation analysis showed that the higher the direct support, emotional support, social interaction support, informational support and total social support score, the lower the total PSQI score of breast cancer patients (r = -0.212, -0.292, -0.236, -0.271, and -0.195 p&lt; 0.01, respectively). Multifactorial model analysis showed that direct support, anxiety and age were the three main factors that affected sleep quality in breast cancer patients. Conclusions:social support may provide a powerful tool to reduce anxiety and improve sleep quality in breast cancer patients with chemotherapy.
Citation Format: Wenjuan Zhu, Wanling Li, Hui Yang, Linying Wang, Jun Guo, Jinnan Gao. The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-05-14.
Abstract P6-05-24: Implementing System Solutions for Survivorship Care Plans
Authors: Alnabulsi Dina , Jackson Gloria L. , Lopez AnaMaria 
Published: March 2023

Abstract
Background: A survivorship care plan (SCP) is a detailed cancer care summary and future care plan that is generally given to a patient upon completion of adjuvant treatment for a cancer diagnosis. The initial goals of SCPs were to educate patients and other health care professionals about the treatments received, make them aware about potential long-term effects of therapy, and emphasize recommendations for future cancer screening and care (1). Due to numerous barriers—scheduling, staffing, and lack of awareness—SCPs are not delivered to all eligible patients. To address this unmet need our multidisciplinary breast clinic (MDBC) established an Advanced Practice Professional (APP) Survivorship Clinic. With the acute impact of the COVID-19 pandemic, survivorship referrals decreased. We, therefore, developed and implemented system solutions to address SCP access. Methods: System solutions include partnering with the Cancer Registry to provide the list of patients potentially in need of survivorship visits, partnering with pharmacy to confirm patient eligibility, creating specifically designated telemedicine survivorship visits in our electronic scheduling system, prospectively scheduling persons identified, engagement of APPs across the MDBC, and establishing a single coordinating point. Numbers of SCPs delivered are tracked monthly and patient satisfaction is assessed through data collected Press Ganey surveys. Results: This presentation will share our process interventions and outcomes as they mature. Our early data demonstrate the efficacy of the workflow and appear promising. Conclusion: We anticipate that system-based solutions will provide more patients with SCPs and demonstrate patient satisfaction. Blaes AH, Adamson PC, Foxhall L, Bhatia S. Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of Cancer. JCO Oncol Pract. 2020 Aug;16(8):447-450. doi: 10.1200/JOP.19.00801. Epub 2020 Apr 8. Erratum in: JCO Oncol Pract. 2020 Nov;16(11):774. PMID: 32267803. Gache, K., Leleu, H., Nitenberg, G. et al. Main barriers to effective implementation of stroke care pathways in France: a qualitative study. BMC Health Serv Res 14, 95 (2014). https://doi.org/10.1186/1472-6963-14-95
Citation Format: Dina Alnabulsi, Gloria L. Jackson, AnaMaria Lopez. Implementing System Solutions for Survivorship Care Plans [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-05-24.
Abstract P6-05-33: Distress Reduction and Physical Activity Enhancement by Mobile Support Group in Breast Cancer Survivors: a randomized controlled study
Authors: Chung Il-Yong , Jung Miyeon , Lee Sae Byul , Lee Jong Won , Ahn Sei Hyun , Chung Haekwon 
Published: March 2023

Abstract
Purpose Improving physical activity (PA) and reducing mental distress are important issues in the treatment of cancer survivors. This study aimed to investigate the effect of a mobile app-based community on enhancing PA and decreasing distress in breast cancer survivors. Methods We conducted a single-center, prospective, non-blinded, randomized controlled study. Subjects who got breast cancer surgery were allocated to a control group or a app-based community group (intervention) where members were able to share their daily physical activities. Daily walk steps and weekly distress scores using app-based Distress Thermometer (DT) questionnaires were collected from participants for 24 weeks. To examine the differences in levels of distress and weekly step counts for 6 months, we used a t-test method and multivariable regression modeling. Results From Jan 2019 to Apr 2020, a total of 202 participants were enrolled in this study. The intervention group showed a significant increase in weekly steps by 4,496 for 6 months (p &lt; 0.001). The participants in the intervention group showed a significantly lower rate of above mild distress (DT≥3, beta[B] = -0.731, p &lt; 0.001) and above moderate distress (DT≥5, B = -0.558, p &lt; 0.001) compared to those in the control group for 6 months. Conclusions The mobile app-based community is an effective and less resource-intensive tool to increase PA and decrease distress in breast cancer survivors.
Citation Format: Il-Yong Chung, Miyeon Jung, Sae Byul Lee, Jong Won Lee, Sei Hyun Ahn, Haekwon Chung. Distress Reduction and Physical Activity Enhancement by Mobile Support Group in Breast Cancer Survivors: a randomized controlled study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-05-33.
Abstract P6-07-01: Costs of breast cancer recurrence after initial treatment for high risk early breast cancer using SEER-Medicare linked data
Authors: Vitko Alexandra S. , Martin Pamela A. , Zhang Sheng , Johnston Adam F. , Ohsfeldt Robert L. , Zheng Shen , Liepa Astra M. 
Published: March 2023

Abstract
Background: Despite the good prognosis with treatment for most patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (EBC), ~ 20–30% of patients experience locoregional or distant disease recurrence. To assist in value assessments of novel therapies in the adjuvant setting, this study aimed to determine the costs of treated breast cancer recurrence following treated EBC.
Methods: This retrospective study analyzed linked patient data from the US Surveillance Epidemiology and End Results (SEER) registry (2010-2014) and Medicare claims (2009 to 2019, which included data from Part A, B, and Prescription Drug Events [Part D]). Data were analyzed for patients aged ≥65 years with HR+, HER2-, node-positive EBC at high risk of recurrence (consistent with monarchE trial high risk criteria). Treated recurrences were defined based on treatment events/procedure codes, including surgery, radiation and systemic therapy, after a 90-day gap following the last treatment for initial EBC. Recurrences were classified based on Medicare claim diagnosis codes or SEER registry data. Extra cost was defined as cost attributable to treated recurrence. Cumulative extra costs were estimated by calculating cost differences between patients with treated vs non/untreated recurrence. Cumulative extra costs were analyzed over the first 6 years following first treated recurrence, a duration which ensured adequate sample size. Costs were inflated to 2021-US$.
Results: We identified 3081 eligible patients (mean age at diagnosis 74.5±7.1 years, 97.4% female, 87.8% White). We identified 964 patients with treated recurrence (distant=432, locoregional=128, contralateral=9, unclassified=347) and 2117 patients with non/untreated recurrence. Six-year cumulative extra costs were higher for patients with distant recurrences ($168,656) than for patients with locoregional recurrences ($96,465) (Table 1).
Conclusions: Cost of recurrence in patients with high risk EBC is considerable, particularly in patients with distant recurrences. Most patients who recurred in this population experienced distant recurrence. Delaying or preventing recurrence may reduce long term costs in these high risk EBC patients.
Table 1. Mean cumulative extra costs attributable to treated recurrence.
Citation Format: Alexandra S. Vitko, Pamela A. Martin, Sheng Zhang, Adam F. Johnston, Robert L. Ohsfeldt, Shen Zheng, Astra M. Liepa. Costs of breast cancer recurrence after initial treatment for high risk early breast cancer using SEER-Medicare linked data [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-07-01.
Abstract P6-10-02: Self-assembled nano drugs of pyrotinib and indocyanine green based on photothermal photodynamic therapy
Authors: Xuhong Juncheng , Deng Jun , Jiang Jun , Qi Xiaowei 
Published: March 2023

Abstract
Background: Photothermal and photodynamic therapy is a new tumor treatment strategy, which can kill tumor cells and reduce the damage to surrounding normal tissues, but the lack of targeting limits its efficacy. In this study, the targeted photothermal and photodynamic nanodrug P/ICG was synthesized by self-assembly of the targeted drug pyrotinib and photosensitizer indocyanine green (ICG), and its application in the photothermal and photodynamic therapy of HER2 positive breast cancer was explored. Method: In this study, the nano drug P/ICG was self-assembly synthesized of pyrotinib and ICG, and its physical parameters and stability were tested. We used 808nm near-infrared light and infrared thermal imager to verify the photothermal effect of nano drugs. Then we used DCFH-DA probe to detect the level of ROS in cells by laser confocal and flow cytometry to verify the photodynamic effect of the nano drug, and verified the antitumor effect of P/ICG combined with near-infrared light irradiation in vitro. We established a PDX mouse breast cancer model and verified the efficacy and safety of P/ICG in the treatment of HER2-positive breast cancer in vitro. Finally, the effect of P/ICG on ferroptosis was verified by MDA, CCK8 and WB experiments. Result: We mixed pyrotinib and ICG in a certain proportion, and purified them by high-speed centrifugation and ultrafiltration to synthesize nano drug P/ICG. P/ICG has good stability and can be effectively ingested by HER2-positive breast cancer cells. Subsequently, we proved through in vitro and in vivo experiments that P/ICG combined with near-infrared light irradiation can significantly inhibit the growth of tumor cells and improve the survival rate of mice. At the same time, P/ICG combined with near-infrared light irradiation increased the phosphorylation of Nrf2 protein, increased the level of free KEAP1 protein, and decreased the levels of SLC7A11, GPX4 and FTH1 protein, significantly increased the lipid peroxidation of tumor cells, and promoted the ferroptosis of tumor cells. Conclusion: Pyrotinib and ICG self-assembled nano drug P/ICG can significantly promote the ferroptosis of HER2-positive breast cancer cells and inhibit the growth of cancer cells, which can be used as a new strategy for the treatment of HER2-positive breast cancer. Key words: pyrotinib; HER2-positive breast cancer; Photothermal therapy; photodynamic therapy
Citation Format: Juncheng Xuhong, Jun Deng, Jun Jiang, Xiaowei Qi. Self-assembled nano drugs of pyrotinib and indocyanine green based on photothermal photodynamic therapy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-10-02.